Related Experiment Videos
[Transplantation in cancer therapy].
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 1, 1987
Summary
Cyclosporin A improved organ transplantation outcomes. Liver transplantation offers a potential cure for unresectable liver tumors, but adjuvant therapies are needed to prevent cancer recurrence.
Area of Science:
- Immunosuppression and Transplantation
- Oncology
- Hepatobiliary Surgery
Context:
- Cyclosporin A, introduced in 1978, revolutionized organ transplantation by improving patient outcomes.
- Organ transplantation is a vital treatment for end-stage organ disease and has emerged as a therapeutic option for primary liver malignancies.
- Surgical resection remains the preferred treatment for liver tumors when feasible.
Purpose:
- To review the role of organ transplantation in treating end-stage diseases and cancer.
- To highlight the potential of liver transplantation for unresectable liver tumors.
- To discuss the challenges and potential improvements in transplantation for malignancy.
Summary:
- Organ transplantation has significantly advanced due to immunosuppressants like Cyclosporin A.
- Liver transplantation is increasingly utilized for primary liver cancers, including fibrolamellar hepatomas, offering long-term survival and cure possibilities.
- Early tumor recurrence post-transplantation, potentially linked to immunosuppression, necessitates further research into adjuvant therapies like chemotherapy.
Impact:
- Improved survival rates and quality of life for patients with end-stage organ failure.
- Expanded therapeutic options for patients with unresectable liver cancer, offering a chance for cure.
- Identified the need for multimodal treatment strategies, combining transplantation with adjuvant therapies, to optimize cancer treatment outcomes.